Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors

医学 血栓弹性成像 部分凝血活酶时间 重组因子VIIa 加药 血友病A 血友病 养生 凝血酶原时间 麻醉 治疗药物监测 外科 凝结 内科学 药代动力学
作者
Xue Qi,Yongqiang Zhao,Kuixing Li,Linyuan Fan,Baolai Hua
出处
期刊:Blood Coagulation & Fibrinolysis [Ovid Technologies (Wolters Kluwer)]
卷期号:25 (7): 754-760 被引量:16
标识
DOI:10.1097/mbc.0000000000000137
摘要

Although the use of bypassing agents has dramatically improved the management of haemophilia in patients with inhibitors, questions remain regarding optimal dosing regimens and methodology for monitoring their clinical effectiveness. In this study, we evaluated the efficacy and safety of two different doses of recombinant activated factor VIIa (rFVIIa) in patients with haemophilia and inhibitors and assessed the feasibility of using thromboelastography (TEG) and thrombin generation assays (TGA) for monitoring the response to rFVIIa. Six patients aged 9-49 years with congenital or acquired haemophilia with inhibitors who experienced a total of nine bleeding episodes were included. Seven episodes were treated with conventional rFVIIa dosing (72.7-109.1 μg/kg), and two episodes were treated with a single high-dose regimen (254.6-264.0 μg/kg). Clinical and haemostatic responses were evaluated. Haemostasis was assessed by prothrombin time (PT), activated partial thromboplastin time (aPTT), factor VII coagulant activity (FVII:C), TEG, and TGA. Six out of seven (85.7%) bleeding episodes responded to conventional rFVIIa dosing, and half (50%) responded to the high-dose regimen. No relationships between PT, aPTT, and FVII:C levels and clinical outcome were observed. However, changes in TEG and TGA parameters tended to correspond to clinical response, although large inter-individual variation in rFVIIa efficacy was noted. A good response was seen with rFVIIa in treating acute bleeding episodes in patients with haemophilia and inhibitors. Because changes in TEG and TGA may correlate with clinical outcomes of rFVIIa, TEG and TGA may be useful for monitoring rFVIIa activity in inhibitor-positive haemophilia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
huang’发布了新的文献求助20
刚刚
7秒前
GXSH发布了新的文献求助10
14秒前
科研通AI2S应助huang’采纳,获得10
19秒前
无为完成签到 ,获得积分10
23秒前
完美世界应助GXSH采纳,获得10
25秒前
xiaohong完成签到 ,获得积分0
30秒前
无花果应助Bonnie采纳,获得10
31秒前
xxxxam完成签到,获得积分10
34秒前
43秒前
Bonnie发布了新的文献求助10
46秒前
老神在在完成签到,获得积分10
47秒前
坚强的广山应助勇往直前采纳,获得10
47秒前
JiangHb完成签到,获得积分10
47秒前
空白完成签到,获得积分10
49秒前
fanconi完成签到 ,获得积分10
51秒前
看文献完成签到,获得积分10
54秒前
Yufan完成签到 ,获得积分10
57秒前
扬帆起航完成签到 ,获得积分10
57秒前
认真绿蝶完成签到 ,获得积分10
59秒前
欣慰歌曲完成签到 ,获得积分10
1分钟前
1分钟前
乐天林完成签到 ,获得积分10
1分钟前
哭泣的映寒完成签到 ,获得积分10
1分钟前
轩轩完成签到 ,获得积分10
1分钟前
木木木完成签到,获得积分10
1分钟前
Ceceliayyy完成签到 ,获得积分10
1分钟前
南风不竞完成签到,获得积分10
1分钟前
《子非鱼》完成签到,获得积分10
1分钟前
SH完成签到,获得积分10
1分钟前
小马甲应助科研通管家采纳,获得10
1分钟前
小马甲应助科研通管家采纳,获得10
1分钟前
Ava应助科研通管家采纳,获得10
1分钟前
脑洞疼应助科研通管家采纳,获得10
1分钟前
wushuimei完成签到 ,获得积分10
1分钟前
1分钟前
wuyanan513发布了新的文献求助30
1分钟前
鞘皮完成签到,获得积分10
1分钟前
kkscanl完成签到 ,获得积分10
2分钟前
Cold-Drink-Shop完成签到,获得积分10
2分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546210
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600310
捐赠科研通 1896399
什么是DOI,文献DOI怎么找? 946273
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557